viewMedlab Clinical Ltd

Medlab Clinical expanding cannabis-based medicines into Europe

By having a European subsidiary, Medlab can save on drug registration fees.

Euro sign
In Australia, Medlab has proceeded to stage II for its cannabis cancer trial

Medlab Clinical Ltd (ASX:MDC) has formally incorporated a wholly owned subsidiary MDC Europe Limited to facilitate expansion into Europe.

The subsidiary will be used specifically for current and future dealings regarding NanaBis™ and the proposed drug registration models as per the European Medicines Agency (EMA). 

NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

European registration of NanaBis™ progressing

Meetings have been held with EMA on the pathway for registration of NanaBis™.

Conditional approval is likely. Registration with a significant fee reduction requires the company to be domiciled in Europe.

Medlab’s CEO Dr Sean Hall said: “MDC as a Group is strategically placed to progress commerce in Europe through potential trade deals, especially in conjunction with the recently announced granting of an export licence for NanaBis™.

“This move is also very exciting as it provides NanaBis™ an introduction into Europe as a potentially future compliant drug.” 

READ: Medlab Clinical proceeding to stage II for cannabis cancer trial

In late October 2018, Medlab successfully completed stage I of the NanaBis™ human trial on cancer patients at Royal North Shore Hospital.

The trial is progressing as planned and currently in stage II of the Ethics approved trial.

This NanaBis™ program will serve as an integral part of both domestic and foreign regulatory approvals.

Quick facts: Medlab Clinical Ltd

Price: 0.145 AUD

Market: ASX
Market Cap: $40.55 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...



Medlab Clinical's Dr Sean Hall details new FeverMates agreement

Medlab Clinical Ltd's (ASX:MDC) Dr Sean Hall caught up with Proactive's Andrew Scott after signing a Heads of Agreement (HoA) with Randall Communications Pty Ltd - trading as FeverMates. The deal will help to expand Medlab’s nutraceutical business in new foreign and domestic...

on 6/4/20

2 min read